Selection for constrained peptides that bind to a single target protein

Posted: 2021-11-04 19:00:00
Peptide secondary metabolites are common in nature and have diverse pharmacologically-relevant functions, from antibiotics to cross-kingdom signaling. Here, we present a method to design large libraries of modified peptides in Escherichia coli and screen them in vivo to identify those that bind to a single target-of-interest. Constrained peptide scaffolds were produced using modified enzymes gleaned from microbial RiPP (ribosomally synthesized and post-translationally modified peptide) pathways and diversified to build large libraries. The binding of a RiPP to a protein target leads to the intein-catalyzed release of an RNA polymerase σ factor, which drives the expression of selectable markers. As a proof-of-concept, a selection was performed for binding to the SARS-CoV-2 Spike receptor binding domain. A 1625 Da constrained peptide (AMK-1057) was found that binds with similar affinity (990 ± 5 nM) as an ACE2-derived peptide. This demonstrates a generalizable method to identify constrained peptides that adhere to a single protein target, as a step towards "molecular glues" for therapeutics and diagnostics.

参考サイト PubMed: covid-19

Powered by Stromvergleich


4月 21, 2020 バイオアソシエイツ


Gilead Sciences社は、世界の保健当局と緊密に協力して、調査用化合物「Remdesivir(レムデシビル)」(画像)の実験的使用を通じ、新型コロナウイルス( COVID-19 )に対応していることを報告した。米国食品医薬品局(FDA)、疾病対策センター(CDC)、保健福祉省(DHHS)、米国立アレルギー感染症研究所(NIAID)、国防総省(DoD)- CBRN Medical、中国CDCおよび国家医療製品管理局(NMPA)、世界保健機関(WHO)、そして個々の研究者と臨床医と共同して、Gilead…

ゲスト 936人 と メンバー 5人 がオンラインです